CDK4 and breast carcinoma: Importantly, they also showed that the combined targeting of HER2 and CDK4/6 in lapatinib/trastuzumab-resistant HER2-positive breast cancer cells caused not only the additive but synergistic inhibition of cell growth and cell viability in vitro.